Drug maker lobby considers legal challenge to drug pricing reforms

Pharmaceutical companies that fought drug pricing reforms Congress passed as part of the Inflation Reduction Act are now weighing a legal challenge as the Biden administration sets about implementing the policy, Axios reports. Pharmaceutical Research and Manufacturers of America, the industry's big Washington trade group, says the Centers for Medicare and Medicaid Services rushed guidance on negotiations out the door. The IRA aims to lower drug costs through steps like capping out-of-pocket prescription costs in Medicare and enables Medicare to directly negotiate with drug manufacturers for some of the costliest drugs.